Trevena Reports Third Quarter 2021 Results
November 15, 2021 07:00 ET
|
Trevena Inc.
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected...
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Second Quarter 2021 Results
August 12, 2021 07:00 ET
|
Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
January 06, 2021 07:00 ET
|
Trevena Inc.
-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa.,...
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
December 10, 2020 08:43 ET
|
Trevena Inc.
-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
Trevena Reports First Quarter 2020 Results
May 07, 2020 07:00 ET
|
Trevena Inc.
Trevena Reports First Quarter 2020 ResultsFDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing collaboration with NIH to...